Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Marco Donia(University of Copenhagen), Inge Marie Svane(Copenhagen University Hospital), Pia Kvistborg(The Netherlands Cancer Institute), Massimo Libra(University of Catania), Per thor Straten(Herlev Hospital), Paolo Fagone(University of Catania), Martin Lauss(Lund University), Anja Müeller(University of Reading), Mads Hald Andersen(Copenhagen University Hospital), Barbara Seliger(Luther University), Eva Ellebæk(Copenhagen University Hospital), Göran Jönsson(Lund University), Sine Reker Hadrup(Herlev Hospital), Rikke Andersen(Herlev Hospital), Katja Harbst(Lund University), Mattias F. Lindberg(Avid Bioservices (United States)), Marit van Buuren(The Netherlands Cancer Institute), Jonas A. Nilsson(The University of Western Australia), Manja Idorn(Aarhus University), Ferdinando Nicoletti(University of Catania), Ton N. Schumacher(Leiden University Medical Center), Henrik Schmidt(Massachusetts Institute of Technology), Shamaila Munir Ahmad(Herlev Hospital)
Cited by 45
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799